Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 1/20 | 0.63 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.63 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.63 |
| ▸ | DUOX2 | Q9NRD8 | 1/20 | 0.63 |
| ▸ | DUOX1 | Q9NRD9 | 1/20 | 0.63 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TLR5 | O60602 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23585073 | 0.86 | CYBB (0.47) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL15313075 | 0.81 | CYBB (0.69) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL29490371 | 0.80 | CYBB (0.66) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4937076 | 0.80 | CYBB (0.66) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL2027831 | 0.77 | CYBB (1.00) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL29368383 | 0.77 | CYBB (1.00) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4941814 | 0.76 | KDM1A (0.66) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4930461 | 0.73 | CYBB (0.57) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4918509 | 0.73 | CYBB (0.57) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL17210872 | 0.73 | CYBB (0.67) | CYBBNOX5NOX4DUOX2DUOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041469-B1 | TREATMENT AND OR PREVENTION OF METASTATIC PROSTATE CANCER | UNIV ARIZONA (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10179142-B2 | Treatment and/or prevention of bone metastasis | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2019-01-15 | — | — | US | disclosed |
| US-20160213693-A1 | TREATMENT AND/OR PREVENTION OF BONE METASTASIS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2016-07-28 | — | — | US | disclosed |
| US-20160213693-A1 | TREATMENT AND/OR PREVENTION OF BONE METASTASIS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2016-07-28 | — | — | US | disclosed |
| WO-2015035072-A1 | TREATMENT AND/OR PREVENTION OF BONE METASTASIS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179142-B2 | Treatment and/or prevention of bone metastasis | TIAM1, CD2BP2, CD4 | CYBB 4310/4885NOX5 4376/4885NOX4 4546/4885 |
| US-20160213693-A1 | TREATMENT AND/OR PREVENTION OF BONE METASTASIS | TIAM1, CD2BP2, CD4 | CYBB 4310/4885NOX5 4376/4885NOX4 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.